In Duchenne muscular dystrophy (DMD), the reading frame of an out-of-frame DMD deletion can be repaired by antisense oligonucleotide (AO)-mediated exon skipping. This creates a shorter dystrophin protein, similar to those expressed in the milder Becker muscular dystrophy (BMD). The skipping of some exons may be more efficacious than others. Patients with exon 44 or 45 skippable deletions (AOs in clinical development) have a less predictable phenotype than those skippable for exon 51, a group in advanced clinical trials. A way to predict the potential of AOs is the study of patients with BMD who have deletions that naturally mimic those that would be achieved by exon skipping.
D uchenne muscular dystrophy (DMD) is caused by frame-disrupting mutations in the DMD gene that prevent the full translation of its protein product, dystrophin.
1,2 Duchenne muscular dystrophy is characterized by progressive muscle weakness and degeneration resulting in loss of ambulation at approximately 13 years of age in the steroid-treated population 3 and death from respiratory and/or cardiac failure in the third or fourth decade of life when supported by noninvasive ventilation. [4] [5] [6] In-frame (IF) dystrophin mutations that do not disrupt the open reading frame typically cause a clinically milder disorder, Becker muscular dystrophy (BMD). 7, 8 The IF mutations result in the translation of an internally deleted dystrophin protein; variations in the amount and functionality of these different dystrophin proteins contribute to the variable phenotypic spectrum of BMD.
9
Dystrophin is a large sarcolemmal protein that forms part of the dystrophin-associated protein complex.
10,11 Dystrophin protects muscle fibers against the mechanical forces of contraction and plays a role in signaling; the loss of dystrophin leads to secondary sarcolemmal protein deficiencies. Antisense oligonucleotide (AO)-mediated exon skipping aims to restore the DMD reading frame to allow the production of an internally deleted dystrophin protein and, hopefully, a functional benefit to patients with DMD who have out-offrame (OOF) deletions. [12] [13] [14] The restoration of dystrophin and members of the dystrophin-associated protein complex has been achieved following local and systemic injections of AOs targeting exon 51. [15] [16] [17] [18] [19] Efforts are now focused on targeting other exons 12, 20 ; however, the skipping of some exons may be more efficacious than others. To predict the potential of various exon skipping strategies, we studied patients with BMD who have deletions that naturally mimic those achieved by exon skipping.
We previously quantified dystrophin in patients with BMD who have IF deletions that mimic skipping of exons 51, 45 through 55, and 53. 21 While these results proved encouraging for exon 51 and 53 skipping, several factors should be considered when developing and assessing the efficacy of strategies for skipping exons 44 and 45, which are among the most common DMD skippable exons. First, the percentage of revertant and trace dystrophin expression in patients with deletions flanking exon 44 is significantly higher than with deletions surrounding exon 51. 22 Second, OOF deletions around exons 44 and 45 result in a variety of clinical severities including intermediate muscular dystrophy (IMD) and BMD.
23-27
Herein, we characterize patients with IF and OOF DMD deletions around exons 44 and 45 to enhance the planning, execution, and analysis of clinical trials for exon 44 or 45 skipping.
Methods
Twenty-one patients ( 28 (confirmed by multiplex ligation-dependent probe amplification) and the availability of a muscle biopsy. A standardized questionnaire was distributed to obtain information on genetic mutation, age at onset, age at biopsy, motor function abilities at the latest assessment, and other comorbidities.
Patients with BMD were classified as asymptomatic, having mild BMD, or having severe BMD according to the age at onset, relevant history, and overall motor function throughout the disease course. Asymptomatic individuals had no detectable muscle weakness and the only pathological feature was an elevated serum creatine kinase level. Mild BMD was defined as having mild proximal muscle weakness but retaining running ability beyond adolescence. Individuals who either lost running ability by the end of adolescence or never ran were classified as having severe BMD.
Skeletal muscle biopsies (14 quadriceps, 4 deltoid, and 3 unknown) were previously obtained with written informed consent. Nondystrophin control muscle biopsies (n = 2, paraspinal and intercostal muscles) were obtained from the MRC Centre for Neuromuscular Diseases Biobank, London (http: //www.cnmd.ac.uk). Biochemical analysis of all samples was performed in London to minimize variability.
Quantitative immunohistochemistry was performed as previously described. 21 A 2-tailed unpaired t test was used for statistical analysis, and statistical significance was set at P = .05. Western blotting was performed as previously described. 21 Dystrophin intensity was normalized to α-actinin using Image Laboratory software (BioRad) and expressed as a percentage of control. Total RNA was extracted, DNase treated, reverse transcribed, and subjected to quantitative polymerase chain reaction as previously described. 29 Three dystrophin TaqMan assays (Applied Biosystems) were used with probes spanning the junctions of exons 19 and 20, 53 and 54, and 73 and 74 ( Table 2) . Starting concentrations were calculated using the LinRegPCR program. 30,31 Data were normalized to myotilin and presented relative to control. A 2-way analysis of variance and Bonferroni posttest were used to determine statistical significance.
Results
We studied a total of 21 patients ( Figure 1A ). Patients 1 and 2 lack the MANDYS106 epitope and patients 17 through 21 lack the MANEX50 epitope; these data points were excluded as they do not represent dystrophin content.
Notable variability was observed between patients with OOF and IF deletions ( Figure 1A and eFigure 1 in Supplement). Patients 3 (with IMD) and 6 (with BMD) had relatively high dystrophin levels (approximately 41.0% and 48.4%, respectively, for MANDYS106), while patients 4 and 5 with DMD had low levels of dystrophin expression (approximately 9.1% and 8.8%, respectively, for MANDYS106). Mean dystrophin levels for the model 45 IF group were significantly higher than at least 1 of the OOF groups with all 3 antibodies ( Figure 1A ).
We compared the mean level of dystrophin protein expression in the IF and OOF groups vs patients with IF and OOF deletions from our previous study on patients with deletions relevant to exon 51 skipping ( Figure 1A) . 21 The level of dystro- Figure 1B) . No dystrophin was detected for patient 7 with DMD, while the patients with BMD had a mean (SD) dystrophin protein expression of 17% (7.5%) of control. In our previous study on patients with BMD mimicking exon 51 skipping, Western blotting revealed a dystrophin level of approximately 65% of control 21 ( Figure 1B ), confirming that dystrophin protein expression in this current BMD cohort is relatively low. It has been suggested that it is the stability rather than the amount of the DMD transcript that determines the level of dystrophin protein and that there is a 5′ to 3′ imbalance in the stability of the dystrophin transcript. [32] [33] [34] [35] We quantified dystrophin messenger RNA (mRNA) and investigated, indirectly, the stability of the dystrophin transcript using TaqMan assays spanning exon junctions 19 and 20, 53 and 54, and 73 and 74 ( Figure 1C and eFigure 2 in Supplement). The relative expression of dystrophin mRNA using a TaqMan assay for the 5′ end of the transcript was similar to control in all 21 patients and the level of dystrophin mRNA does not correlate to the level of dystrophin protein ( Figure 1 , and eFigure 1 and eFigure 2 in Supplement). We observed a decrease in transcript levels in some patients with the exon junction 53 and 54 assay (ie, 3′ to the deletion breakpoint) that was more pronounced in patients with OOF deletions. Model 45 OOF and model 45 IF group means were statistically different with the exon junction 73 and 74 probe (P = .03) ( Figure 1C) Figure 1C ). 
Quantification of Dystrophin-Associated Protein Expression
To assess the functional properties of the different dystrophin proteins expressed in our cohort, we quantified the expression of β-dystroglycan, neuronal nitric oxide synthase (nNOS), and utrophin by quantitative immunohistochemistry ( Figure 2 and eFigure 3 in Supplement). (Table 2 ) and the mean threshold cycle (Ct) value per sample were used to calculate the starting concentration (N0) using the equation N0 = N t /E Ct where N t is the fluorescence threshold and E is the efficiency. Data were normalized to myotilin, and dystrophin transcript expression is presented as mean (SD) relative to control. (Figure 2) , reflecting the lower level of dystrophin observed in this study; conversely, the β-dystroglycan levels in the OOF groups were higher than in patients with OOF deletions mimicking exon 51 skipping (Figure 2 ). 21 All but 1 (patient 9) of the 21 patients have incomplete nNOS-binding domains (encoded by exons 42-45); consequently, these patients have virtually absent levels of nNOS expression, with patient 9 having the highest level of 8.8%. Sarcolemmal nNOS protein expression was significantly lower with the model 45 IF group compared with both OOF groups (Figure 2) .
There is limited information on the levels of the dystrophin homolog utrophin in BMD or to what extent utrophin and dystrophin are present together at the sarcolemma. (Figure 1 and eFigure 3 in Supplement). We found no obvious difference in the mean or spread of dystrophin or dystrophin-associated protein expression between patients with BMD of different severities (eFigure 1 and eFigure 3 in Supplement). We previously demonstrated that the levels of dystrophin and some dystrophin-associated proteins are correlated with clinical severity in a BMD cohort mimicking exon 51 skipping. 21 Herein, we found no clear correlation between dystrophin, β-dystroglycan, nNOS, or utrophin protein expression and clinical severity for the model 45 group. Asymptomatic patients, those with mild BMD, and those with severe BMD have comparable dystrophin and dystrophinassociated protein levels ( Figure 3 ).
Discussion
We have quantitatively assessed the levels of dystrophin transcript and protein in a cohort of 21 patients with IF and OOF deletions around exons 44 and 45. We compared these data with our previous study 21 to provide the most comprehensive characterization of patients with BMD mimicking exon skipping to date. Our data provide a robust baseline for the assessment of dystrophin transcript and protein levels in boys with DMD recruited into future clinical trials. Patients in the model 44/45 OOF group had higher levels of dystrophin protein than those modeling exon 51 or 53 skipping. We attribute this to a higher level of revertant and trace dystrophin expression in patients in the model 44/45 OOF group.
22,39 Exon 44 skips spontaneously when surrounding exons are deleted 40 ; patients with these "leaky" mutations pre- sent with unpredictable phenotypes, which highlights the limitation of an exclusively genetic diagnosis and the value of accurate muscle pathology. Indeed, 4 of 9 patients in our OOF cohort had IMD or BMD phenotypes instead of the expected DMD phenotype. This is in stark contrast to OOF deletions further 3′ around exon 51, which predictably present as DMD. 21, 41 Although in vitro data suggest that patients with leaky mutations might be ideal candidates for exon skipping, 39 the consequences of the higher background levels of dystrophin and the lower level of dystrophin protein restoration that could be achieved by exon skipping in these patients are unknown. The efficacy and efficiency of exon 44 and 45 AOs will thus be difficult to measure without pretreatment biopsies and sensitive quantitative methods. Phase I and II clinical trials of exon 44 and 45 AOs are under way (ClinicalTrials.gov identifiers NCT01037309 and NCT01826474, respectively); in light of the discussed data, patients with different treatment responses in these trials are likely. The higher level of dystrophin expression in patients eligible for exon 44 or 45 trials may influence their immunity to dystrophin. 42 Immunity to self-and nonselfdystrophin epitopes requires further investigation and should be assessed in future DMD clinical trials. In our study, recruitment may be biased toward patients with severe BMD as many patients with asymptomatic BMD pass undiagnosed. On this note, we could not recruit any patients with BMD who have deletions mimicking exon 44 skipping; thus, our cohort cannot represent the full spectrum of deletions in this area, some of which have never been reported. Nevertheless, all patients with IF deletions in this study had dystrophin protein levels approximately 40% of control and 9 of 12 patients had mild BMD or were asymptomatic. Although our sample size is too small for meaningful analysis, we considered our previous cohort of IF deletions around exon 51 less severe (and the dystrophin protein more stable and/or Antisense oligonucleotide-mediated exon skipping relies on the availability of the dystrophin transcript. Our finding that patients with IF and OOF deletions have 5′ DMD transcript expression levels comparable to control is supported by studies suggesting that transcript stability rather than amount is important for high levels of dystrophin protein expression. 35, 48 We show that all 12 patients with IF deletions had a stable transcript, while all patients with an OOF deletion (accompanied by a low level of dystrophin expression) had an unstable dystrophin transcript. This is supported by another study that showed a 5′ to 3′ increase in threshold cycle values in patients with DMD who have OOF deletions and point mutations. 49 Taken together, these data highlight the need for careful consideration of the location of primers and probes when quantifying dystrophin mRNA and suggest that transcript stability correlates with protein production better than overall transcript levels. Whether exon skipping restores the stability of the dystrophin transcript in vivo and how existing patient transcript instabilities (which may vary according to the OOF mutation) affect the outcome of exon skipping remain to be determined. The assessment of DMD transcript stability could be explored as a marker of response to therapy. Recent data show that the transcript imbalance is more pronounced in mdx mice harboring a nonsense mutation vs wild type. 35 Thus, a strategy to restore and maintain DMD transcript stability may improve the efficiency of AO-mediated exon skipping. In summary, our data suggest that, as with exon 51, AO-mediated exon skipping of exon 44 or 45 may prove beneficial to patients with DMD, as patients with IF mutations in this region had a predominantly mild BMD phenotype. However, we highlight that the skipping of different exons will likely yield different levels of dystrophin protein restoration as well as dystrophin proteins that differ in their stability and functionality.
